TE News: TE Connectivity opens Denver-area IVD facility

PARKER, Colo. – July 26, 2023 – TE Connectivity, a global industrial technology leader, is opening a new Denver area facility to bolster its medical microfluidic manufacturing capabilities. The Parker, Colorado, site will focus on the contract development and production of polymer-based microfluidic devices, which facilitate rapid and accurate diagnosis, personalized treatments and novel therapies vital to the healthcare industry. The expansion will increase TE’s efficiency and expedite the manufacturing and delivery of microfluidic devices to the market.

Spanning over 56,000 square feet, the facility features a state-of-the-art clean room (ISO 7) and is equipped for high-volume manufacturing of microfluidic devices and critical components essential to the in vitro diagnostics (IVD) market. This includes both liquid and dry reagent formats, enabling TE to meet the growing demand for advanced diagnostics and life science research.

The new Parker site, which will eventually replace the current Denver area facility in Englewood, Colorado, complements existing facilities that support the design and manufacturing of microfluidic devices in Carlsbad, California, and Mondragon, Spain. This global footprint enables TE to collaborate with customers located in major global markets dedicated to life science research and advanced diagnostics.

Over the next few years, this expansion is expected to generate around 100 new jobs, for a total of about 200 in the Denver area, contributing to economic growth and development.

"We are thrilled to expand our presence in the Denver area and strengthen our commitment to the development and manufacturing of microfluidic products," said Uwe Winzen, general manager of TE’s IVD business. "This new facility will allow us to better serve our customers in the diagnostics and life sciences industry, ensuring we can meet and exceed the development and high-volume manufacturing needs of any current and future partners."

This new facility reinforces TE’s position as a global leader in microfluidic technology and demonstrates a commitment to advancing healthcare solutions through design, clinical validation (CRO) and contract manufacturing. The company's expanded manufacturing capabilities in the United States and Europe will further facilitate the maintenance of critical supply chains, ensuring a reliable and efficient flow of essential medical devices.